Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T19:48:22.843Z.
Calculation as of: 2026-10-06T19:48:22.843Z.
Quote observation: 2026-10-06T19:45:21.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 69a1d57d3f318828ebe19021960b74268097702d5d6050a421f3255bba496414
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
MoonLake Immunotherapeutics
Market Cap
$921.28M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$911.43M
Price/OCF Ratio
12.70
TTM Avg
11.45
3Y Avg
13.28
5Y Avg
14.23
Market Cap
$943.21M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$889.91M
Price/OCF Ratio
N/A
TTM Avg
1973.56
3Y Avg
1192.17
5Y Avg
1192.17
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | $921.28M | N/A | N/A | N/A | N/A |
| CeriBell, Inc. (CBLL)vs › | $921.77M | N/A | N/A | N/A | N/A |
| Kura Oncology, Inc. (KURA)vs › | $926.34M | N/A | 6.63 | 6.62 | 6.62 |
| HealthStream, Inc. (HSTM)vs › | $911.43M | 12.70 | 11.45 | 13.28 | 14.23 |
| Seaport Therapeutics, Inc. Common Stock (SPTX)vs › | $943.21M | N/A | N/A | N/A | N/A |
| Aktis Oncology, Inc. (AKTS)vs › | $953.01M | N/A | N/A | N/A | N/A |
| Arbutus Biopharma Corp (ABUS)vs › | $889.91M | N/A | 1973.56 | 1192.17 | 1192.17 |
| Savara Inc. (SVRA)vs › | $959.06M | N/A | N/A | N/A | N/A |
| Bioventus Inc. (BVS)vs › | $886.49M | 9.15 | 9.21 | 23.47 | 25.52 |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $882.11M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
